CANCER PROGRESS 2020 PANELS:

  • Paradigm-shifting platforms I, IO: Taking IO to the next Level
  • Paradigm-shifting platforms II, Non-IO: Targeting Better, Targeting the Intractable
  • Investing into Oncology: Who, What and Where?
  • Vaccines: From Paleo to Neo, Cancer Vaccines in the New Age of IO
  • Next Wave of Diagnostics, Including Precision IO: Early and Smarter, the Better to Cure
  • Inflecting Value in Early Stage Biotech ( in an Increasingly Cost Conscious Environment): Linking Proof of Relevance to Pricing & Reimbursement

AND INTRODUCING: ADVANCED THERAPEUTICS – ½ DAY SESSION

  • Antigen/platform pairings (“Forget Wine and Cheese…Get this Right and Your Valuation Takes Flight”)
  • State of the union for off-the-shelf (“In an ‘Allo or Bust’ Market, What’s Rising to the Top of the Shelf?”)
  • What are investors and partners looking for today (“How to Stand Out/Inflect Value in a Frothy Vat of Cells”)

Thank You to our 2019 Sponsors and Supporters

Venue

Convene at 32 Old Slip
32 Old Slip, New York, NY 10005 | 1.888.730.7307
http://convene.com/location/financial-district-downtown-nyc/

Testimonials

“I truly enjoyed the conference. I told several colleagues and friends that this has been one of the best conferences I have ever attended.”

Christoph Lengauer, Chief Scientific Officer

Blueprint Medicines

“What an unbelievable 2-day event that was. The intimate atmosphere (I made great new contacts) and dynamic (sometimes “dynamic tension”) interaction between panel members was fantastic. I kept great notes and have already shared the very enthusiastic feedback & takeaways with my management team.”

Armand Girard, Vice President, Corporate Development

GlycoMimetics

“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”

Noemi Rosa

Novartis

“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”

Richard Brian Gaynor, Sr. Vice President Global Development / Medical Affairs, Oncology Business Unit

Eli Lilly and Company